




# NIH Policy Updates

**Christy Leake**  
**Grants Administration Branch**  
**National Institute of General**  
**Medical Sciences, NIH**





# Grant Closeout Requirements

---

[NIH GPS 8.6 Closeout](#): Recipients must submit the all closeout documents within 120 calendar days of the end of the period of performance (project period)

- Final Research Performance Progress Report (F-RPPR)
- Final Invention Statement and Certification (FIS)
- Final Federal Financial Report (FFR) – must ensure that there are no discrepancies between the final FFR expenditure data (in eRA Commons) and the FCTR in the PMS



# Grant Closeout Requirements

---

- HHS policy requires NIH to initiate unilateral closeout procedures within 180 days of the period of performance end date if any of the closeout reports are not timely and acceptable
- Sanctions may include, but are not limited to, corrective actions, removal of authorities, and/or delay or withholding of further awards



# Interim and Final Progress Reports

- [NOT-OD-17-022](#): The Final Research Performance Progress Report (F-RPPR) has replaced the Final Progress Report (FPR) for closeout
  - The general format is the same as the interim/annual RPPR
  - Recipients are required to report on Project Outcomes
  - Due dates have not changed
- [NOT-OD-17-037](#): Implementation of the Interim-RPPR while a Renewal Application is Under Consideration - Effective 02/09/2017
  - ~~Old policy whether funded or not, the progress report contained in the renewal (Type 2) application may serve in lieu of a separate final progress report~~
  - If the recipient organization has submitted a renewal application on or before the date by which a Final-RPPR would be required for the current competitive segment, then submission of an Interim-RPPR via eRA Commons is required no later than 120 calendar days from the period of performance end date
    - If the renewal application is funded, NIH will treat the Interim-RPPR as the annual performance report for the final year of the previous competitive segment.
    - If the renewal application is not funded, the Interim-RPPR will be treated by NIH staff as the institution's Final-RPPR.



# Human Subjects System (HSS)

---

- [NOT-OD-18-179](#): Transition from Inclusion Management System to New Human Subjects System (HSS) as of June 9, 2018
- Consolidates human subjects and clinical trial information in one place
- NIH migrated enrollment records previously in IMS to HSS
- PIs and SOs can access HSS via a *Human Subjects* link in the *Status* section of eRA Commons and via a *Human Subjects* link in the *RPPR* section of eRA Commons
- [https://era.nih.gov/hss\\_overview.cfm](https://era.nih.gov/hss_overview.cfm)



# Human Subjects System (HSS)

- The HSS will allow recipients to:
  - Add/update study information
  - Create new enrollment reports or view/edit/update existing enrollment data
  - Make off-cycle corrections or updates after application or Research Performance Progress Report (RPPR) submission
  - Convert a delayed onset study to a full study record, once detailed study information is available
  - Access and update all human subject and clinical trial data associated with their applications or grants in one place



# Clinical Trials

---

- [NOT-OD-16-148](#): Expects all NIH-funded investigators and staff who are involved in the conduct, oversight, or management of clinical trials be trained in Good Clinical Practice (GCP) – Effective 01/01/2017
- [NOT-OD-16-149](#): Expects all NIH-funded clinical trials are registered and that results are submitted to ClinicalTrials.gov whether or not subject to FDAAA – Applies to grants, contracts, and intramural clinical trials submitted on or after 01/18/2017
- [NOT-OD-17-043](#): All grant applications with plans to conduct clinical trials must be submitted in response to an FOA which specifically states that clinical trials are allowed – Effective 01/25/2018
- [NOT-OD-17-114](#): Active FOAs with due dates on or after 01/25/2018 were updated to state whether clinical trial are or are not allowed



# Clinical Trials

---

- If there is a research or pilot project on an IDeA award, additional information and documentation will be required when it is submitted for prior approval to NIGMS
- Terms specific to each clinical trial will be included in SECTION IV – GM Special Terms and Conditions on the NoA





# NIH Forms

---

## [NOT-OD-17-119](#): New NIH "FORMS-E" Grant Application Instructions Available for Due Dates On or After January 25, 2018

- Consolidation of human subjects, inclusion enrollment, and clinical trial information previously collected across multiple agency forms
- Expansion and use of discrete form fields for clinical trial information
- Incorporation of recent Grants.gov changes to R&R Budget and SBIR/STTR Information forms
- Make sure you are using the current forms for all applications and prior approval requests

# Questions?

---

## NIGMS GAB DRCB Team

Christy Leake	<a href="mailto:Christy.Leake@nih.gov">Christy.Leake@nih.gov</a>	GAB DRCB Team Leader
<i>Grants Management Specialists</i>		<i>IDeA State Assignments</i>
Arina Kramer	<a href="mailto:Arina.Kramer@nih.gov">Arina.Kramer@nih.gov</a>	Montana, New Hampshire, Oklahoma, South Dakota
Brian Iglesias	<a href="mailto:Brian.Iglesias@nih.gov">Brian.Iglesias@nih.gov</a>	Alaska, Nevada, North Dakota, Rhode Island
Courtney Tardd-Wright	<a href="mailto:Courtney.Tardd-Wright@nih.gov">Courtney.Tardd-Wright@nih.gov</a>	Nebraska, Kansas, West Virginia, Vermont
Emily Tran	<a href="mailto:Emily.Tran@nih.gov">Emily.Tran@nih.gov</a>	Delaware, Maine, Mississippi, New Mexico
Lisa Hildred	<a href="mailto:Lisa.Hildred@nih.gov">Lisa.Hildred@nih.gov</a>	Arkansas, Hawaii, Idaho, South Carolina
Samantha Farrell	<a href="mailto:Samantha.Farrell@nih.gov">Samantha.Farrell@nih.gov</a>	Kentucky, Louisiana, Puerto Rico, Wyoming